The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
Open accessAbstract
Phosphoinositide-3-kinase (PI3K)-α inhibitors have shown clinical activity in squamous cell carcinomas (SCCs) of head and neck (H&N) bearing PIK3CA mutations or amplification. Studying models of therapeutic resistance, we have observed that SCC cells that become refractory to PI3Kα inhibition maintain PI3K-independent activation of the mammalian target of rapamycin (mTOR). This persistent mTOR activation is mediated by the tyrosine kinase receptor AXL. AXL is overexpressed in resistant tumors from both laboratory models and patients treated with the PI3Kα inhibitor BYL719. AXL dimerizes with and phosphorylates epidermal growth factor receptor (EGFR), resulting in activation of phospholipase Cγ (PLCγ)-protein kinase C (PKC), which, in turn, activates mTOR. Combined treatment with PI3Kα and either EGFR, AXL, or PKC inhibitors reverts this resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“AXL inhibition has been reported to sensitize drug-resistant mesenchymal tumor cells to anticancer agents, including antimitotic agents, epidermal growth factor receptor (EGFR) inhibitors, and PI3K inhibitors”
From Hypoxic control of metastasis (2016) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,044
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature reviews. Cancer · doi:10.1038/nrc839 · Cited by 6,155
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,109
Self-citationPlatinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726
Kamangar, F., Dores, G. M., & Anderson, W. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2308 · Cited by 3,434
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C. L., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,541
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,214
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Cited by
Sorted by citations
Items 201–300 of 339
Adaptive mechanisms of resistance to anti-neoplastic agents
Ferreira, B. I., Lie, M. K., Engelsen, A. S. T., Machado, S., Link, W., & Lorens, J. B. (2016) · MedChemComm · doi:10.1039/c6md00394j · Cited by 14
Qigesan reduces the motility of esophageal cancer cells via inhibiting Gas6/Axl and NF-κB expression
Kong, L., Wu, Z., Zhao, Y., Lu, X., Shi, H., Shugang, L., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20190850 · Cited by 14
Pan-cancer single cell RNA-seq uncovers recurring programs of cellular heterogeneityPreprint
Kinker, G. S., Greenwald, A., Tal, R., Orlova, Z., Cuoco, M. S., McFarland, J. M., Warren, A. C., Rodman, C., Roth, J. A., Bender, S. A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/807552 · Cited by 14
ZDHHC11-mediated AXL palmitoylation promotes osimertinib resistance in non-small-cell lung cancer
Cui, H., Cai, X.-T., Qian, Q., Fan, S., Li, T. X., Wang, T., Dai, H., Song, Y., Sun, X., & Cao, P. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2502778122 · Cited by 13
Majumder, A., Hosseinian, S., Stroud, M., Adhikari, E., Saller, J. J., Smith, M. A., Zhang, G., Agarwal, S., Creixell, M., Meyer, B. S., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0275 · Cited by 14
Ishida, K., Ito, C., Ohmori, Y., Kume, K., Sato, K. A., Koizumi, Y., Konta, A., Iwaya, T., Nukatsuka, M., Kobunai, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02548-9 · Cited by 13
Xing, H., Gao, M., Wang, Y., Zhang, X., Shi, J., Wang, X., Liu, X., Ma, Q., Kong, X., Yang, C., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.835 · Cited by 13
Chen, Y., Zhang, Y., Chen, S., Liu, W., Lin, Y., Zhang, H., & Yu, F. (2021) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13021 · Cited by 12
Self-citationBenhima (1962) · Présence Africaine · doi:10.3917/presa.042.0147 · Cited by 13
Choe, J. H., Mazambani, S., Kim, T. H., & Kim, J. (2021) · Cells · doi:10.3390/cells10030606 · Cited by 14
Wang, G., Ouyang, B., Jing, F., & Dai, X. (2022) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2023.27.1.21 · Cited by 11
AXL Tyrosine Kinases: A Growing Isoform Family That Promotes Cancer Pathogenesis
Gjerstad, M. E., Aehnlich, P., Gélébart, P., & McCormack, E. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3841 · Cited by 12
van Aalen, E. A., Wouters, S. F. A., Verzijl, D., & Merkx, M. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c00297 · Cited by 11
Gustafsson, A., Fritz, H. K. M., & Dahlbäck, B. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.03.040 · Cited by 11
Leveraging Genomics for Head and Neck Cancer Treatment
Kemmer, J. D., Johnson, D. E., & Grandis, J. (2018) · Journal of dentistry research · doi:10.1177/0022034518756352 · Cited by 10
John, L., George, M., Dcunha, L., Nisar, M., Sanjeev, D., Pahal, P., Gopalakrishnan, A. P., Shivamurthy, P. B., Sreelan, S., Yandigeri, T., et al. (2024) · Journal of Proteins and Proteomics · doi:10.1007/s42485-024-00147-7 · Cited by 10
Zhou, X., Lie, L., Liang, Y. Y., Xu, H., Zhu, B., Huang, Y., Zhang, L., Zhang, Z., Li, Q., Wang, Q., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752466 · Cited by 10
Remer, E., Badarni, M., Hikri, E., Dayan, A., Levi, L., Popovtzer, A., Iraqi, M., Porgador, A., Joshua, B., Bachar, G. Y., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103214 · Cited by 10
Self-citationAlkhatib, D. Z. R., Truong, T. T. K., Fujii, S., Hasegawa, K., Nagano, R., Tajiri, Y., & Kiyoshima, T. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154493 · Cited by 10
Proteolysis of TAM receptors in autoimmune diseases and cancer: what does it say to us?
Malikova, I., Worth, A., Aliyeva, D., Khassenova, M., Kriajevska, M. V., & Tulchinsky, E. M. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07480-9 · Cited by 10
Life Factors and Melanoma: From the Macroscopic State to the Molecular Mechanism
Wang, H., Zhang, H., Zhou, Y., Li, C., & Guo, W. (2025) · Advanced Science · doi:10.1002/advs.202501388 · Cited by 10
Self-citationAntitumor Applications of Polyphenol-Conjugated Turnip Mosaic Virus-Derived Nanoparticles
Velázquez-Lam, E., Tomé‐Amat, J., Segrelles, C., Yuste-Calvo, C., Asensio, S., Peral, J., Ponz, F., & Lorz, C. (2022) · Nanomedicine · doi:10.2217/nnm-2022-0067 · Cited by 9
Pidkovka, N. A., & Belkhiri, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1079041 · Cited by 9
A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer
Su, C.-M., Chang, T.-Y., Hsu, H., Lai, H., Li, J., Lyu, Y.-J., Kuo, K.-T., Huang, M., Su, J.-L., & Chen, P. (2016) · Oncotarget · doi:10.18632/oncotarget.11737 · Cited by 9
Accelerating AXL targeting for TNBC therapy
Khera, L., & Lev, S. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106057 · Cited by 9
The Elongin BC Complex Negatively Regulates AXL and Marks a Differentiated Phenotype in Melanoma
Schieven, S. M., Traets, J. J. H., Vliet, A. V., Baalen, M. V., Song, J., Guimaraes, M. D. S., Kuilman, T., & Peeper, D. S. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0648 · Cited by 10
Fatty acid uptake activates an AXL–CAV1–β-catenin axis to drive melanoma progressionPreprint
Chocarro‐Calvo, A., Jociles-Ortega, M., García-Martínez, J. M., Louphrasitthiphol, P., Carvalho-Marques, S., Vivas, Y., Ramírez-Sánchez, A., Chauhan, J. S., Fiuza, C., Durán, M., et al. (2025) · Genes & Development · doi:10.1101/gad.351985.124 · Cited by 9
Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable
Codilupi, T., Szybinski, J., Arunasalam, S., Jungius, S., Dunbar, A. J., Stivala, S., Brkić, Š., Albrecht, C., Vokálová, L., Yang, J. L., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0163 · Cited by 8
Wu, D., Zeng, H., Tan, J., Xu, Q., Khan, F. A., Pandupuspitasari, N. S., Yang, S., & Huang, C. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s545163 · Cited by 9
Das, A., Bhattacharya, B., & Roy, S. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.12.025 · Cited by 8
New twists in the AXL(e) of tumor progression
Halmos, B., & Haura, E. B. (2016) · Science Signaling · doi:10.1126/scisignal.aai7619 · Cited by 9
Busch, C., Hagel, C., Becker, B., Oetting, A., Möckelmann, N., Droste, C., Möller‐Koop, C., Witt, M., Blaurock, M., Loges, S., et al. (2022) · Cancers · doi:10.3390/cancers14071829 · Cited by 8
Behrmann, C. A., Ennis, K. N., Sarma, P., Wetzel, C., Clark, N. A., Handorf, K. M. V., Vallabhapurapu, S., Andreani, C., Reigle, J. K., Scaglioni, P. P., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0631 · Cited by 7
Prospects of current AXL-targeting therapies in early phase cancer trials
Yim, J., Hope, C., Huelse, J. M., & Graham, D. K. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2511178 · Cited by 8
NFX1‐123: A potential therapeutic target in cervical cancer
Chintala, S., Dankoski, M. A., Anbarasu, A., Ramaiah, S., Miryala, S. K., & Katzenellenbogen, R. A. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28856 · Cited by 7
IQGAP1 binds the Axl receptor kinase and inhibits its signaling
Gorisse, L., Li, Z., Hedman, A. C., & Sacks, D. B. (2018) · Biochemical Journal · doi:10.1042/bcj20180594 · Cited by 7
Li, J., Liu, K., Zhang, T., Yang, Z., Wang, R., Chen, G., & Kang, M. (2018) · Europe PMC (PubMed Central) · Cited by 7
Liu, X., Wang, B.-B., Wang, Y., Wang, Y., Yang, C., Tan, C., Zhang, X., He, Q., Ding, J., & Meng, L. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0085-2 · Cited by 7
Mannella, V., Boehm, K., Celik, S., Ali, T., Mirza, A. N., Hasnaouy, M. E., Kaffa, A., Lyu, Y., Golahmadi, D. K., Leigh, I. M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073567 · Cited by 7
Komatsu, M., Nakamura, K., Takeda, T., Chiwaki, F., Banno, K., Aoki, D., Takeshita, F., & Sasaki, H. (2022) · Oncogene · doi:10.1038/s41388-022-02256-3 · Cited by 7
Navigating TAM receptor dynamics in tumour immunotherapy
Yang, J., Chen, G., Wang, R. Y., Song, C., & Yi, H. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03879-z · Cited by 7
Palacios‐García, J., Sanz‐Flores, M., Asensio, A., Alvarado, R., Berciano, S. R., Stamatakis, K., Paramio, J. M., Cano, A., Nieto, M. A., García‐Escudero, R., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32838 · Cited by 6
SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth
Mills, K. A., Roach, S. T., Quinn, J. M., Guo, L., Beck-Noia, H., Lomonosova, E. E., Ilivicky, A. R., Starks, C. M., Lawrence, J. A., Hagemann, A. R., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.08.008 · Cited by 6
Coleman, N., Subbiah, V., Pant, S., Patel, K. P., Roy‐Chowdhuri, S., Yedururi, S., Johnson, A. M., Yap, T. A., Rodon, J. A., Shaw, K. R. M., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00240-w · Cited by 6
Self-citationWang, J., Al-Majid, D., Brenner, J. C., & Smith, J. D. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00993-3 · Cited by 6
Lan, Y., Yu, Z., Lou, J., Ma, X., & Zhang, B. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1512582 · Cited by 6
Identifying key mutations of radioresponsive genes in esophageal squamous cell carcinoma
Xu, X., Wang, Y., Bai, Y., Lü, J., Guo, Y., Wang, X., Rong, L., Tang, J., Ma, X., Ma, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001173 · Cited by 5
Korovina, I., Elser, M., Borodins, O., Seifert, M., Willers, H., & Cordes, N. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116217 · Cited by 5
Foley, C. N., Qu, S., Paladugu, S. R., Lamani, M., Grange, R. L., Sharif, E. U., Thomas, J., Nareddy, P. R., Zhao, G., Chen, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00238 · Cited by 5
Self-citationFeasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma
Theurer, J., Stecho, W., Yoo, J. J., Kwan, K. F., Wehrli, B. M., Harry, V. V., Black, M. D., Pinto, N. C., Winquist, E., Palma, D. A., et al. (2015) · Pathology & Oncology Research · doi:10.1007/s12253-015-9970-3 · Cited by 5
Han, S., Wang, Y., Ge, C., Gao, M., Wang, X., Wang, F., Sun, L., Li, S., Dong, T., Dang, Z., et al. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9169 · Cited by 5
Synergistic inactivation of AXL: a (cross)road to cure ovarian cancer?
Zurzolo, C. (2018) · EMBO Reports · doi:10.15252/embr.201846492 · Cited by 5
Nguyen, T. T. L., Tarapore, E., & Atwood, S. X. (2019) · Wiley eBooks · doi:10.1002/9783527814633.ch5 · Cited by 6
Carotenoids Modulate FoxO ‐Induced Cell Cycle Arrest in Human Cancer Cell Lines: A Scoping Review
Lee, Z. X., Guo, H., Looi, A. D., Bhuvanendran, S., Magalingam, K. B., Lee, W.-L., & Radhakrishnan, A. K. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70100 · Cited by 4
Liu, C.-A., Harn, H., Chen, K.-P., Lee, J.-H., Lin, S., & Chiu, T. (2022) · Journal of Oncology · doi:10.1155/2022/3236058 · Cited by 4
Mechanisms of Resistance to PI3K and AKT Inhibitors
Castel, P., & Scaltriti, M. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_6 · Cited by 5
Self-citationChen, L., Du, L., Zhang, L., Xie, S., Zhang, X., & Li, H. (2020) · Journal of Molecular Histology · doi:10.1007/s10735-020-09869-6 · Cited by 4
Pishkari, S., Hadavi, R., Koochaki, A., Razaviyan, J., Paryan, M., Hashemi, M., & Mohammadi‐Yeganeh, S. (2021) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2020-0050 · Cited by 4
Development of personalized molecular therapy for acute myeloid leukemia
Engen, C., Hajjar, E., & Gjertsen, B. T. (2015) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201016666150930115024 · Cited by 4
Pharmacological PI3K inhibition in head and neck squamous cell carcinoma: A systematic review
Alves, L., Moura, A., dos Santos, J. A., Borges, G. Á., & Guerra, E. N. S. (2023) · Toxicology in Vitro · doi:10.1016/j.tiv.2023.105558 · Cited by 3
Lazzari, C., Verlicchi, A., Γκουντάκος, Α., Pilotto, S., Santarpía, M., CHAIB-OUKADOUR, I., Ramírez, J. L., Viteri, S., Morales-Espinosa, D., Dazzi, C., et al. (2016) · Pulmonary Therapy · doi:10.1007/s41030-016-0013-3 · Cited by 4
Self-citationBdarny, M., Prasad, M., Balaban, N., Joshua, B., Dinur, A. B., Grenman, R. A., Cohen, L., & Elkabets, M. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/415752 · Cited by 3
Self-citationChocarro‐Calvo, A., Jociles-Ortega, M., García-Martínez, J. M., Louphrasitthiphol, P., Vivas, Y., Ramírez-Sánchez, A., Chauhan, J. S., Fiuza, C., Durán, M., García‐Jiménez, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.21.576568 · Cited by 3
Badarni, M., Gabbay, S., Elkabets, M., & Rotblat, B. (2023) · Biology · doi:10.3390/biology12070988 · Cited by 2
Self-citationEmerging AXL Inhibitors in Oncology: Chemical and Biological Advances in Targeted Cancer Therapy
Shah, K., Gopal, K., Kumar, S., & Saha, S. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206351185241209053053 · Cited by 2
Morozumi, K., Kawasaki, Y., Sakamoto, I., Sato, T., Maekawa, M., Takasaki, S., Yamashita, S., Mano, N., & Ito, A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118492 · Cited by 2
FOXO transcriptional activity is associated with response to chemoradiation in EAC
Creemers, A., van der Zalm, A. P., van de Stolpe, A., Holtzer, L., Stoffels, M., Hooijer, G. K. J., Ebbing, E. A., van Ooijen, H., van Brussel, A., Aussems-Custers, E. M. G., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03376-w · Cited by 2
Dual inhibition of EGFR and PI3K with a single drug
Katerji, M., Rubin, M. R., & Brognard, J. (2024) · Nature Cancer · doi:10.1038/s43018-024-00806-0 · Cited by 2
Novel Targeted Agents in Head and Neck Squamous Cell Carcinoma
Velho, P. H. I., de Castro, G., & Chung, C. H. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.07.006 · Cited by 2
Role of Receptor Tyrosine Kinase AXL in Cancer
Kumar, R., Tanwar, P., Bhatia, D. D., & Solanki, R. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-93894-8_4 · Cited by 1
Crosstalk Mechanisms Following Targeted Therapy in Head and Neck Cancer
Byeon, H. K. (2016) · Korean Journal of Otorhinolaryngology - Head and Neck Surgery · doi:10.3342/kjorl-hns.2016.59.3.181 · Cited by 1
Roles for AXL and MERTK in Resistance to Cytotoxic and Targeted Therapies
Summers, R. J., Minson, K. A., DeRyckere, D., & Graham, D. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813753-6.00003-2 · Cited by 1
Jia, W., & Cheng, X. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083565 · Cited by 1
Targeting the ErbB Family in Head and Neck Cancer
Kiseleva, A. A., Beck, T. N., Serebriiskii, I. G., Liu, H., Burtness, B. A., & Golemis, E. A. (2018) · Current cancer research · doi:10.1007/978-3-319-78762-6_2 · Cited by 1
TAM family proteins and therapy resistance
McDaniel, N. K., Fischbach, S. R., Ondracek, O. J., Welke, N. B., Iida, M., & Wheeler, D. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817868-3.00008-1 · Cited by 1
Creixell, M., Taylor, S. D., Gerritsen, J. S., Bae, S. Y., Jiang, M., Augustin, T., Loui, M., Boixo, C., Creixell, P., White, F. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.20.563266 · Cited by 1
Active Liposomal Targeting for Head and Neck Squamous Cell Carcinoma TreatmentPreprint
del Campo-Balguerías, A., Martín-Hernández, C., Herrero-Igartua, C., de Andrés, F., Gueddari, A., Garcı́a-Bravo, M., Ocaña, A., Bravo, I., Alonso‐Moreno, C., & Lorz, C. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.6250427 · Cited by 1
Hedberg, M. L. (2015) · D-Scholarship@Pitt (University of Pittsburgh)
Targeting glutamine metabolism inPIK3CAmutant colorectal cancers
Feng, X., Hao, Y., & Wang, Z. (2016) · Molecular & Cellular Oncology · doi:10.1080/23723556.2016.1210561
Integrated Molecular Profiling as an Approach to Identify PI3K Inhibitor Resistance Mechanisms
Michmerhuizen, N. L., Wang, J., & Brenner, J. C. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92875
José Baselga M.D., Ph.D. (1959–2021) leading cancer researcher and oncologist
Elkabets, M., & Blandino, G. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01966-y
Self-citationInglot, M. (2014) · Politeja · doi:10.12797/politeja.11.2014.29.29
Halmos, B., & Liu, X. (2015) · Springer eBooks · doi:10.1007/978-1-4614-6613-0_114-1
Halmos, B., & Liu, X. (2017) · Springer eBooks · doi:10.1007/978-1-4419-0717-2_114
The Role of AXL Receptor Tyrosine Kinase in Cancer Cell Plasticity and Therapy Resistance
Lotsberg, M. L., Davidsen, K. T., Peters, S. D., Haaland, G. S., Rayford, A. J., Lorens, J. B., & Engelsen, A. S. T. (2022) · Springer eBooks · doi:10.1007/978-3-030-98950-7_18
Jhaveri, K. L., Chang, M. T., Juric, D., Saura, C., Gambardella, V., Melnyk, A., Patel, M. R., Ribrag, V., Ma, C. X., Aljumaily, R. M., et al. (2023) · doi:10.1158/1078-0432.22479515.v1
Self-citationJhaveri, K. L., Chang, M. T., Juric, D., Saura, C., Gambardella, V., Melnyk, A., Patel, M. R., Ribrag, V., Ma, C. X., Aljumaily, R. M., et al. (2023) · doi:10.1158/1078-0432.c.6530237
Self-citationJhaveri, K. L., Chang, M. T., Juric, D., Saura, C., Gambardella, V., Melnyk, A., Patel, M. R., Ribrag, V., Ma, C. X., Aljumaily, R. M., et al. (2023) · doi:10.1158/1078-0432.c.6530237.v1
Self-citationMahmud, M., Munjal, A., Savani, M., Win, H., Rozell, U., & Arshad, J. (2024) · Foregut The Journal of the American Foregut Society · doi:10.1177/26345161241238748
Role of TAM Receptors in Antimalarial Humoral Immune Response
John, L., & Vijay, R. (2024) · Pathogens · doi:10.3390/pathogens13040298
Gu, Z., Shi, C., Li, J., Han, Y. P., Sun, B., Zhang, W., Wu, J., Zhou, G., Ye, W., Jiang, L., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19753347
AXL: A novel therapeutic target in IBD
Saeedi, B. J., Carr, H. E., Higgins, P., & Steiner, C. A. (2024) · Advances in pharmacology · doi:10.1016/bs.apha.2024.10.009 · Cited by 1
Dziubek, K., Faktor, J., Lokhande, K. B., Shrivastava, A., Papak, I., Chruściel, E., Pilch, M., Hupp, T., Marek-Trzonkowska, N. M., Singh, A., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01935-w
Wang, J., Ludwig, M., Kulkarni, A., Birkeland, A. C., Michmerhuizen, N. L., Gensterblum‐Miller, E., Zhai, J., Jiang, H., Swiecicki, P. L., Buchakjian, M. R., et al. (2025) · Head & Neck · doi:10.1002/hed.70048
Ruicci, K. M., Meens, J., Plantinga, P., Stecho, W., Pinto, N. C., Yoo, J., Fung, K., MacNeil, D., Mymryk, J. S., Barrett, J. W., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13100910
Peng, X., Huang, X., Lulu, T. B., Jia, W., Zhang, S., Cohen, L., Huang, S., Fan, J., Chen, X., Liu, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26693185
Self-citationPeng, X., Huang, X., Lulu, T. B., Jia, W., Zhang, S., Cohen, L., Huang, S., Fan, J., Chen, X., Liu, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26693140
Self-citationPeng, X., Huang, X., Lulu, T. B., Jia, W., Zhang, S., Cohen, L., Huang, S., Fan, J., Chen, X., Liu, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26693152
Self-citationPeng, X., Huang, X., Lulu, T. B., Jia, W., Zhang, S., Cohen, L., Huang, S., Fan, J., Chen, X., Liu, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26693137
Self-citation
Metadata
- Authors
- Elkabets, M., Pazarentzos, E., Juric, D., Sheng, Q., Pelossof, R. A., Brook, S., Benzaken, A. O., Rodon, J., Morse, N., Yan, J. J., Liu, M., Das, R., Chen, Y., Tam, A., Wang, H., Liang, J., Gurski, J. M., Kerr, D. A., Rosell, R., Teixidó, C., Huang, A., Ghossein, R. A., Rosen, N., Bivona, T. G., Scaltriti, M., & Baselga, J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of California, San Francisco (US)
- Massachusetts General Hospital (US)
- Vall d'Hebron Institute of Oncology (ES)
- Hospital Universitario Dexeus (ES)
- Corresponding author
- Scaltriti, Maurizio
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 27
- Issue
- 4
- Pages
- 533-546
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC4398915
- OpenAlex
- W2039071845
- Cited by
- 325
- References
- 42
- Citations by year
- 2026: 4 · 2025: 18 · 2024: 31 · 2023: 27 · 2022: 36 · 2021: 28 · 2020: 36 · 2019: 34 · 2018: 31 · 2017: 29 · 2016: 41 · 2015: 8
- FWCI
- 15.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- Soochow University
- National Cancer Institute (R01CA169338, DP2CA174497, P30CA008748, K12CA087723, T32CA071345)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- AXL receptor tyrosine kinase, EGFR, protein kinase C, mTOR signaling, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, PIK3CA mutation, alpelisib, phospholipase C-gamma, combination therapy, treatment resistance
- MeSH terms
- Cetuximab, Esophageal Squamous Cell Carcinoma, Phosphoinositide-3 Kinase Inhibitors, Axl Receptor Tyrosine Kinase, Animals, Carcinoma, Squamous Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Humans, Protein Kinase C, Proto-Oncogene Proteins, Thiazoles, Signal Transduction, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Receptor Protein-Tyrosine Kinases, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Class I Phosphatidylinositol 3-Kinases, TOR Serine-Threonine Kinases, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
